MedTrace Logo

Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer

NCT00202800 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-06-02

No results posted yet for this study

Summary

Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer.

Conditions

Interventions

DRUG

Gemcitabine, Etoposide

Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer

Sponsors & Collaborators

  • Van Andel Research Institute

    collaborator OTHER

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Battle Creek Health System

    collaborator OTHER

  • Mercy Health System

    collaborator NETWORK

  • Metropolitan Hospital, Michigan

    collaborator OTHER

  • Mecosta County General Hospital

    collaborator UNKNOWN

  • Munson Medical Center

    collaborator OTHER

  • Saint Mary's Health Network

    collaborator OTHER

  • Spectrum Health Hospitals

    lead OTHER

Principal Investigators

  • Marianne Lange, MD · Grand Rapids Clinical Oncology Program

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2007-09-30
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00202800 on ClinicalTrials.gov